SEC Filings include 13F quarterly reports, 13D/G events and more. Andrew Booth occupies the position of Chairman of Precision NanoSystems, Inc. and Chief Financial Officer of AbCellera Biologics, Inc. Mr. Booth is also Director-National Board at Canadian Manufacturers & Exporters. IBD . Mr. Thermopylae Holdings Ltd is the largest individual ABCELLERA BIOLOGICS shareholder, owning 55.22M shares representing 19.41% of the company. In connection with his appointment as CFO, Andrew will step down from AbCellera's Board of Directors, where he has served for the past four years. AbCellera Biologics Inc. (AbCellera) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. which has allowed us to embark on unprecedented antibody research," chief financial officer Andrew Booth said in a recent . is a former United States Naval Officer (Lieutenant Commander) with 10 years of service in active and reserve forces. . Andrew Booth, MBA Chief Financial Officer. The shares were purchased at an average price of $5.79 per share, for a total transaction of $492,150.00. Based on historical compounded. Canada (604) 559-9005 : Charles S. Kim. There are 4 companies in the AbCellera Biologics Inc corporate family. Veronique Lecault. This analysis is for one-year following each trade, and the results are theoretical . ABCELLERA BIOLOGICS. Member of the Board of Directors. . Employment Agreement between the Registrant and Andrew Booth, dated April 12, 2019 (incorporated by reference to Exhibit 10.9 of the Registrant's Registration Statement on Form S . Shortly after the Q1 earnings release, CEO Carl Hansen bought a whopping 1,708,468. Andrew Booth. The shares were bought at an average price of . AbCellera Biologics Inc. develops antibody discovery platform. . Detailed Profile of BOOTH ANDREW portfolio of holdings. Andrew Booth Jr. (born September 28, 2000) is an American football cornerback for the Minnesota Vikings of the National Football League (NFL). Following the transaction, Booth now owns 130,959 shares of the . This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. Andrew Booth, AbCellera Biologics Inc: Profile and Biography - Bloomberg Markets Andrew Booth is Chief Financial Officer at AbCellera Biologics Inc. See Andrew Booth's compensation, career history,. BC Tech has been lobbying the federal and provincial governments for a combined $41M investment to implement the ScaleUP BC platform. Prior to joining AbCellera, from June 2017 to December 2021, Mr. Aubuchon was the Global Marketing Lead for Amgen's General Medicine early portfolio, . Abcellera Biologics, Inc. Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Carl. Total Funds Raised: $303.9M . Mr. Booth has served . AbCellera Biologics Inc. 2215 Yukon Street. /s/ Andrew Booth : Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) December 10, 2020: Andrew Booth * Director : What is Andrew Booth's net worth? . Mr. Booth said AbCellera now . The company was established in 2012 and is headquartered out of Vancouver, B.C. Still, "we remain optimistic at the prospect of long-term revenue stream from Covid products," AbCellera Chief Financial Officer Andrew Booth said on the company's earnings conference call. Erika Kinney. AbCellera Biologics Inc. sec form 4 filings insider trading, insiders stock buying and selling. Vancouver, Canada (October 18, 2016) - AbCellera is pleased to announce it has appointed Andrew Booth to its Board of Directors. They will be joining the privately-held therapeutic antibody discovery company as chief financial officer and general counsel, respectively. AbCellera Biologics Inc. (NASDAQ:ABCL - Get Rating) CFO Andrew Booth acquired 85,000 shares of the stock in a transaction dated Thursday, May 12th. In connection with his appointment as CFO, Andrew will step down from AbCellera's Board of Directors, where he has served for the past four years. See the company profile and updated insider trades of Abcellera Biologics Inc (ABCL). Andrew Booth. Company profile for AbCellera Biologics Inc. including key executives, insider trading, ownership, revenue and average growth rates. Andrew Booth, Insider at Abcellera Biologics (NASDAQ:ABCL), made a large insider buy on November 11, according to a new SEC filing. Richard Segal. Chief Financial Officer. AbCellera has announced two key additions to its leadership team - Andrew Booth, formerly of STEMCELL Technologies, and Tryn Stimart, formerly of Gibbons P.C. NDP government of moving into "herd immunity mode" on COVID-19 Why British Columbia is especially vulnerable to the effects of a climate breakdown 45 things to do in . Starting from a clean slate, we've replaced. This strategic investment will build on the competitive advantages of the BC tech sector, support the growth of over 800 BC technology companies, create 10,000 incremental clean jobs and grow a more robust, green, diverse and globally exporting economy for BC For the past 10 years, Abcellera has been laser focused on this one thing, reinventing and rebuilding a new frontend for therapeutic antibody industry. stock was originally listed at a price of $50.01 in Dec 14, 2020. Legal, IP & Compliance. During his 10-year tenure, STEMCELL grew from approximately $40 million in revenue and 250 employees to $250 million in revenue and over 1,300 employees worldwide, establishing . ABCL Cash And Cash Equivalents as of today (June 06, 2022) is $545.7 Mil. * Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 5 filed on 02/03/2022; 4 filed on 12/10/2021; 4 filed on 12/09/2021; 4 filed on . In depth view into AbCellera Biologics Short-Term Debt & Capital Lease Obligation explanation, calculation, historical data and more . Vancouver, BC V5Y 0A1. Company profile for AbCellera Biologics Inc. including key executives, insider trading, ownership, revenue and average growth rates. AbCellera Biologics Inc (US:ABCL) has 160 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). The estimated net worth of Andrew Booth is at least $1.04 million as of May 12th, 2022. Net worth is estimated to be at least $37.06M AbCellera Biologics Inc. ABCL : Booth Andrew: Lecault Veronique: Hansen Carl L. G. Thermopylae Holdings Ltd. Where To Trade ABCL. Andrew Booth, Insider at Abcellera Biologics (NASDAQ:ABCL), made a large insider buy on November 11, according to a new SEC filing. Mr Booth is 47, he's been the Chief Financial Officer of AbCellera Biologics since . Nov 15, 2021 CFO of Abcellera Biologics Inc ( 30-Year Financial, Insider Trades) Andrew Booth ( insider trades) bought 67,500 shares of ABCL on 11/11/2021 at an average price of $14.71 a share. AbCellera Biologics Inc. develops antibody discovery platform. Tryn T. Stimart. AbCellera has announced two key additions to its leadership team - Andrew Booth, formerly of STEMCELL Technologies, and Tryn Stimart, formerly of Gibbons P.C. Andrew holds a Master of Business Administration from INSEAD (2003) and a B.ASc. ABCL Cash Flow from Operations as of today (June 06, 2022) is $235.3 Mil. Funding Timeline edit_note Submit a Deal. "It is part of the overall equation," said Andrew Booth, AbCellera's chief financial officer, in an interview with The Logic. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. The shares were purchased at an average price of $5.79 per share, for a total transaction of $492,150.00. Andrew Booth, Insider at Abcellera Biologics (NASDAQ:ABCL), made a large insider buy on November 11, according to a new SEC filing. AbCellera Biologics Inc. (NASDAQ:ABCL - Get Rating) CFO Andrew Booth bought 85,000 shares of the stock in a transaction that occurred on Thursday, May 12th. AbCellera works in partnerships with researchers from academia, n. Stage: Public. ABCL Shares Outstanding (Basic Average) as of today (June 06, 2022) is 283.9 Mil. What Happened: A Form 4 filing from the U.S. Securities and . There are 2 older and 3 younger executives at AbCellera Biologics. AbCellera is a biotech company focused on providing a full-stack, artificial intelligence-, or AI, powered drug discovery platform. They will be joining the privately-held therapeutic antibody discovery company as chief financial officer and general counsel, respectively. In depth view into AbCellera Biologics Shares Outstanding (Basic Average) explanation, calculation, historical data and more Veronique Lecault. In depth view into AbCellera Biologics Long-Term Debt & Capital Lease Obligation explanation, calculation, historical data and more Andrew Booth, Chief Financial Officer, on May 12, 2022, executed a purchase for 85,000 shares in . "AbCellera is well prepared for the sprint to find antibodies. Bamlanivimab has brought AbCellera US$526-million in royalties to date, providing a "non-dilutive source of funding," chief financial officer Andrew Booth said. Learn more about ABCL's sector, industry, classification, workforce size and executives on MSN Money. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering . View insider buying and selling activity for AbCellera Biologics or view top insider-selling stocks. Following the transaction, Booth now owns 130,959 shares of the . in Engineering Physics from the University of British Columbia (1998). AbCellera Biologics Inc has 10 total employees across all of its locations and generates $2.35 million in sales (USD). AbCellera General Information Description. Booth Andrew C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER, A1 : Chief Financial Officer: Signatures /s/ Tryn Stimart, attorney-in-fact: 5/16/2022 ** Signature of Reporting Person: Date: Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Finance & BD. Chief financial officer Andrew Booth said during a conference call with analysts that AbCellera expects first quarter revenue of US$190-million to US$210-million, mostly from royalties . AbCellera-discovered COVID-19 antibody has treated +400K patients, potentially preventing more than 20K hospitalizations . In depth view into AbCellera Biologics Cash And Cash Equivalents explanation, calculation, historical data and more View Andrew Booth's professional profile on LinkedIn. STEMCELL is a global leader that supports life science research and biotechnology with a wide range of specialty cell . AbCellera is a privately held company located in Vancouver, Canada, that is a world-leading innovator in antibody discovery for therapeutics, and immune profiling for vaccine research. Divakar Gupta. Andrew Booth joins AbCellera from STEMCELL Technologies, where he held roles of Vice President of Instrumentation, Chief Financial Officer, and Chief Commercial Officer. Andrew Booth. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. . Prior to joining AbCellera, from June 2017 to December 2021, Mr. Aubuchon was the Global Marketing Lead for Amgen's General Medicine early portfolio, . For the complete insider trading history of ABCL, click here . Andrew Booth. In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Andrew Booth in ABCL / AbCellera Biologics Inc. This net worth approximation does not reflect any other assets that Mr. Booth may own. Andrew Booth Chief Financial Officer: 500000: Gift at $ 0 . Funding Products Partners People Awards & Patents News Network . Tryn Stimart, JD. Andrew currently serves as Chief Financial Officer for Vancouver-based STEMCELL Technologies Inc., Canada's largest biotechnology company. Andrew Booth, Insider at Abcellera Biologics (NASDAQ:ABCL), made a large insider buy on November 11, according to a new SEC filing. add_circle. LinkedIn is the world's largest business network, helping professionals like Andrew Booth discover inside connections to recommended job candidates, industry experts, and business partners. If you had invested in ABCELLERA BIOLOGICS stock at $50.01, your return over the last 1 years would have been -84.92%, . Andrew Booth joins AbCellera from STEMCELL Technologies, where he held roles of Vice President of Instrumentation, Chief Financial Officer and Chief Commercial Officer. Andrew Weaver accuses B.C. Andrew Booth. Following the completion of the acquisition, the chief financial officer now owns [] AbCellera has spent much of the year focused on COVID-19, partnering with pharmaceutical giant Eli Lilly on a treatment that began human testing last month. In connection with his appointment as CFO,. Mr. Andrew Booth is a Chief Financial Officer at AbCellera Biologics, Inc., a Chairman at Precision NanoSystems, Inc. and a Director-National Board at Canadian Manufacturers & Exporters. Mr. Booth owns 138,500 shares of AbCellera Biologics stock worth more than $1,044,290 as of June 4th. Andrew holds a Master of Business Administration from INSEAD (2003) and a B.ASc. Ester Falconer Ph.D. Chief Technology . The oldest executive at AbCellera Biologics Inc. is Tryn T. Stimart Esq., 51, who is the Chief Legal Officer & Corp. Sec.. The process went like lightning. in Engineering Physics from the University of British Columbia (1998). He played college football at Clemson University and was drafted by the Vikings in the second round of the 2022 NFL Draft. Tiffany Chiu, BSc Vice President, . ABCL Long-Term Debt & Capital Lease Obligation as of today (June 06, 2022) is $36.4 Mil. Find the latest AbCellera Biologics Inc. (ABCL) stock discussion in Yahoo Finance's forum. Vancouver, Canada (October 18, 2016) - AbCellera is pleased to announce it has appointed Andrew Booth to its Board of Directors. Andrew Booth. AbCellera works in partnerships with researchers from academia, non-profit organizations, and industry to enable and accelerate . (Sales figure is modelled). During his 10-year tenure, STEMCELL grew from approximately $40 million in revenue and 250 employees to $250 million in revenue and over 1,300 employees worldwide, establishing . After delivering the 2020 financial results on Monday, chief financial officer Andrew Booth said he expects the company's revenue to come in at between US$190 million and US$210 million for the . It would certainly appear that insiders at AbCellera have been paying very close attention to these developments. . Following the completion of the acquisition, the chief financial officer now owns [] Learn more on insiders at ABCL. Andrew Booth Chief Financial Officer: 500000: Gift at $ 0 . Carl Hansen. Andrew Booth, Chief Financial Officer, AbCellera (left) and Tryn Stimart, General Counsel, AbCellera (right) (Photo: Business Wire) September 05, 2019 06:08 AM Eastern Daylight Time Market / Outlet Security Exchange Symbol Type; Abcellera Biologics / AbCellera Biologics Inc. Common Shares: US XNAS: ABCL: EQ0000000067033660 AbCellera Biologics Inc is a biotechnology company. AbCellera Biologics. Company insiders that have sold AbCellera Biologics company stock in the last year include Andrew Booth, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, Michael R Hayden, and Veronique Lecault. Mr. Booth has served . In depth view into AbCellera Biologics Cash Flow from Operations explanation, calculation, historical data and more